AMSTERDAM, Netherlands and SANTA CLARA, Calif., April 22 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of molecular diagnostics, and Agilent Technologies, Inc. (NYSE: A), today announced terms under which they intend to collaborate to develop new in-vitro diagnostic tests. In addition, the two companies announced an agreement in which Agendia products will continue to be supplied on Agilent microarrays through December 31, 2011. Agilent has been manufacturing the components for the Agendia assay since its inception in 2003. The financial terms of the agreement were not disclosed.
"We've established and enjoyed a strong business relationship with Agilent since the incorporation of Agendia," said Dr. Bernhard Sixt, CEO and co- founder of Agendia. "These activities, including joint research and development, have allowed our two companies to forge an even closer strategic alliance focused on Agendia's core competencies, namely the discovery of biomarkers and development of new diagnostic tests for clinical use, which are regulated under the new IVDMIA guidelines of the FDA."
"We're proud that Agendia has selected Agilent to move forward with their critical work in diagnosing breast cancer," said Yvonne Linney, Ph.D., vice president and general manager, Genomics at Agilent. "We eagerly anticipate expanding our role beyond the manufacturing of Agendia products on the Agilent microarrays to helping them build validated diagnostic cancer tests, as well as developing and expanding the company's worldwide distribution channels."
Last year, Agendia's MammaPrint(R), a molecular diagnostic tool
developed to help physicians make informed decisions in treating breast
cancer, became the first IVDMIA microarray
|SOURCE Agendia BV|
Copyright©2008 PR Newswire.
All rights reserved